A phase II study of pomalidomide, daily oral cyclophosphamide, and dexamethasone in relapsed/refractory multiple myeloma.

Oliver Van Oekelen,Samir Parekh,Hearn Jay Cho,Nivetha Vishnuvardhan,Deepu Madduri,Joshua Richter,Chun Ip,Kenneth Lau,Erika Florendo,Ines Stefania Mancia,Joanne Thomas,Daniel Verina,Elaine Chan,Katarzyna Zarychta,Lisa La,Gina Strumolo,David Melnekoff,Violetta V. Leshchenko,Seunghee Kim-Schulze,Suzana Couto,Maria Wang,William E. Pierceall,Anjan Thakurta,Alessandro Laganà,Sundar Jagannath,Ajai Chari

A phase II study of pomalidomide, daily oral cyclophosphamide, and dexamethasone in relapsed/refractory multiple myeloma.

2020

Relapsed/refractory multiple myeloma patients treated with pomalidomide and dexamethasone have an overall response rate (ORR) of ∼30% and median progression-free survival (PFS) of 4–5 months. Previ...

Keywords:

Dexamethasone
Multiple myeloma
Cyclophosphamide
Medicine
Internal medicine
Oncology
Phases of clinical research
Pomalidomide
relapsed refractory
oral cyclophosphamide
overall response rate

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations